Kirichenko O. Valsartan and vitamins B-group in the pharmacotherapy of hypertension

The thesis is devoted to the problem of optimizing the diagnosis and treatment of hypertension and possibilities of pharmacological correction of cognitive decline in these patients. Essential hypertension is a predictor of cognitive decline, which is apparent from the second stage of disease. Cognitive decline affected by the stage of the disease, the degree of blood pressure and duration of the underlying disease. Hypertension is accompanied by serum homocysteine elevation, ranging from the ІІnd stage (14.68±0.57 mmol/l) compared to the control group, without significant difference between patients with the IInd and IIIrd stage of the disease. Increased serum homocysteine is associated with cognitive dysfunction in the short-term memory domain and less affect the reaction rate of the patients. Pharmacotherapy of hypertension by valsartan (80-160 mg/day for 3 months) contributes the daily blood pressure reduction and optimization of circadian rhythm, and for clinical efficacy it is comparable to amlodipine. Addition to complex of antihypertensive drug therapy combination of Neurorubine forte lactab, and folic acid (1 mg/day) can reduce plasma homocysteine levels by 22.7 %. Amlodipine antihypertensive therapy does not impair cognitive function of patients. Valsartan therapy improves reaction rate of patients. Normalization of homocysteine improves short-term memory of patients.